CPT-SR02

CPT-SR02 is a preclinical small molecule modulator of the sphingosine-1-phosphate receptor 1 (S1PR1) being developed by Mercaptor Discoveries for the treatment of multiple sclerosis and neuropathic pain. The compound is engineered using Mercaptor's proprietary Captor-Prodrug Technology (CPT), which creates "injury-activated" therapeutics designed to remain inactive in healthy tissue and release the active moiety only at sites of oxidative stress or inflammation. This approach is intended to enhance the therapeutic window of S1PR1 modulation by concentrating the drug's effects within the central nervous system or at sites of nerve injury while reducing systemic exposure and associated toxicities.